Background/aim: Advances in chemotherapy for gastric cancer have encouraged surgeons to perform conversion surgery following a response to first-line chemotherapy in patients with initially unresectable gastric cancer. In this study we evaluated the efficacy of conversion surgery following first- or second-line chemotherapy for unresectable gastric cancer.
Patients And Methods: We retrospectively analyzed clinicopathological and survival data of 94 patients with unresectable gastric cancer treated with first- (n=94) or second-line (n=43) chemotherapy.
Results: Patients who converted to surgery following first- (n=26) or second-line (n=5) chemotherapy had significantly longer survival times than those treated with chemotherapy alone (n=63) (p<0.01). Survival length did not differ significantly between patients converted to surgery following first- and second-line chemotherapy. Among 31 patients who underwent conversion surgery, one initial non-curative factor (odds ratio(OR)=0.49; 95% confidence interval (95%CI)=0.22-0.95; p=0.03) was the only significant independent predictor of longer survival in multivariate Cox regression analysis.
Conclusion: Patients with unresectable gastric cancer initially exhibiting one noncurative factor may obtain survival benefit from conversion surgery after a response to both first- and second-line chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.13010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study.
ESMO Open
January 2025
Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy.
Background: Nivolumab-based therapies are efficacious with acceptable safety in patients with gastric cancer (GC) and gastroesophageal junction cancer (GEJC). Novel nivolumab-based combination immunotherapies may offer enhanced efficacy in these indications. FRACTION-GC was a signal-seeking, randomized, open-label, phase II adaptive-design trial assessing efficacy and safety of nivolumab in combination with ipilimumab [cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody], relatlimab (lymphocyte-activation gene 3 antibody), or IDO1i (BMS986205, an indoleamine-2,3-dioxygenase-1 inhibitor) in patients with unresectable, advanced/metastatic GC/GEJC.
View Article and Find Full Text PDFMetastatic pancreatic cancer now in remission: a case report and literature review.
Discov Oncol
January 2025
Hematology Oncology Associates of CNY, Syracuse, USA.
Pancreatic cancer is a highly aggressive malignancy with the majority of patients presenting at a late stage with unresectable or metastatic disease. Even with first line treatment, median survival is approximately 11 months in patients with advanced PDAC. This report details the unique case of a patient that presented with peritoneal metastases from an adenocarcinoma of the body of the pancreas, had a remarkable response to palliative chemotherapy and is alive without evidence of disease 12 months following cessation of all active treatment.
View Article and Find Full Text PDFGastric cancer liver metastases in China: a real-world, multicentre, prospective, observational cohort study protocol.
BMJ Open
January 2025
Department of General Surgery, First Medical Center, Chinese PLA General Hospital, Beijing, China
Introduction: Gastric cancer liver metastases (GCLM) is a highly heterogeneous disease with a poor prognosis. The multidisciplinary diagnosis and treatment model is applied throughout the entire treatment process. In addition to the previous RECORD study, which was based on the C-GCLM classification system developed by our team, there is a lack of recent data on patient baseline characteristics, clinical treatment and efficacy evaluation.
View Article and Find Full Text PDFZolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature.
Cureus
December 2024
Subir Chowdhury School of Quality and Reliability, Indian Institute of Technology, Kharagpur, IND.
Article Synopsis
- Zolbetuximab is a chimeric monoclonal antibody designed to target the Claudin 18.2 protein, which is overexpressed in certain gastrointestinal cancers, notably gastric and gastroesophageal junction adenocarcinomas.
- This drug initiates an immune response to attack cancer cells when combined with standard chemotherapy regimens, and it has been approved as a first-line treatment for advanced, unresectable cancers in specific patient populations.
- Clinical trials show that zolbetuximab significantly improves progression-free survival and overall survival rates compared to chemotherapy alone, while maintaining a relatively safe profile for patients.
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Gastric Cancer
December 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Article Synopsis
- The study examined the prevalence and characteristics of MSI-high tumors in patients with metastatic or recurrent gastric cancer (GC) that had not yet undergone chemotherapy.
- MSI-high GC was found in 5.6% of patients, with higher prevalence in females, individuals aged 70 and older, tumors located in the lower stomach, HER2-negative cases, and patients without liver metastases.
- Understanding these MSI-high tumors can enhance clinical practices and inform future research targeting this specific subtype of GC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!